公开(公告)号：US20070060598A1

公开(公告)日：2007-03-15

申请号：US11411413

申请日：2006-04-26

申请人： Ronald Albers ,  Leticia Ayala ,  Steven Clareen ,  Maria Delgado Mederos ,  Robert Hilgraf ,  Sayee Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne Sloss ,  Elise Sudbeck ,  Jonathan Wright

发明人： Ronald Albers ,  Leticia Ayala ,  Steven Clareen ,  Maria Delgado Mederos ,  Robert Hilgraf ,  Sayee Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne Sloss ,  Elise Sudbeck ,  Jonathan Wright

IPC分类号： A61K31/52 ,  C07D473/14

CPC分类号： A61K31/52 ,  C07D473/32

摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

摘要翻译： 本文提供具有以下结构的氨基嘌呤化合物：其中R 1，R 2和R 3如本文所定义，包含有效量的组合物 的氨基嘌呤化合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症，炎性病症，黄斑变性，缺血再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关的方法 条件，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症，包括向有需要的患者施用有效量的氨基嘌呤化合物。

公开(公告)号：US20060287344A1

公开(公告)日：2006-12-21

申请号：US11332617

申请日：2006-01-12

申请人： Ronald Albers ,  Leticia Ayala ,  Steven Clareen ,  Maria Delgado Mederos ,  Robert Hilgraf ,  Sayee Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne Sloss ,  Elise Sudbeck ,  Jonathan Wright

发明人： Ronald Albers ,  Leticia Ayala ,  Steven Clareen ,  Maria Delgado Mederos ,  Robert Hilgraf ,  Sayee Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne Sloss ,  Elise Sudbeck ,  Jonathan Wright

IPC分类号： A61K31/52 ,  C07D473/14

CPC分类号： C07D473/00 ,  A61K31/52 ,  C07D473/32

摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

摘要翻译： 本文提供具有以下结构的氨基嘌呤化合物：其中R 1，R 2和R 3如本文所定义，组合物包含有效的 氨基嘌呤化合物的量和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症，炎性病症，黄斑变性，缺血再灌注损伤，疼痛及相关综合征，疾病相关性消耗，石棉 - 相关病症，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症，包括向有需要的患者施用有效量的氨基嘌呤化合物。

公开(公告)号：US07723340B2

公开(公告)日：2010-05-25

申请号：US11332617

申请日：2006-01-12

申请人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Sayee G. Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S. S. Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright ,  Ian Henderson ,  Andrew G. Cole

发明人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Sayee G. Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S. S. Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright ,  Ian Henderson ,  Andrew G. Cole

IPC分类号： C07D473/32 ,  A61K31/52 ,  A61F2/82 ,  A61P3/10 ,  A61P11/00 ,  C07D239/50 ,  C07D239/48

CPC分类号： C07D473/00 ,  A61K31/52 ,  C07D473/32

摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

摘要翻译： 本文提供具有以下结构的氨基嘌呤化合物：其中R1，R2和R3如本文所定义，包含有效量的氨基嘌呤化合物的组合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症 ，炎性病症，黄斑变性，缺血再灌注损伤，疼痛及相关综合征，疾病相关性消耗，石棉相关病症，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症，包括施用有效量的 氨基嘌呤化合物对需要的患者。

公开(公告)号：US08101588B2

公开(公告)日：2012-01-24

申请号：US12404413

申请日：2009-03-16

申请人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Sayee G. Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S. S. Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright

发明人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Sayee G. Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S. S. Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright

IPC分类号： C07D473/32 ,  C07F5/02 ,  A61K31/52 ,  A61K31/69 ,  A61P3/10 ,  A61P11/00 ,  C07D239/50 ,  C07D239/48

CPC分类号： A61K31/52 ,  C07D473/32

摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

摘要翻译： 本文提供具有以下结构的氨基嘌呤化合物：其中R1，R2和R3如本文所定义，包含有效量的氨基嘌呤化合物的组合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症， 炎性病症，黄斑变性，缺血再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关病症，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症包括给予有效量的氨基嘌呤 与需要的患者复合。

公开(公告)号：US20090312320A1

公开(公告)日：2009-12-17

申请号：US12540013

申请日：2009-08-12

申请人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Sayee G. Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S.S. Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright ,  Ian Henderson ,  Andrew G. Cole

发明人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Sayee G. Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S.S. Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright ,  Ian Henderson ,  Andrew G. Cole

IPC分类号： A61K31/52 ,  A61K31/5377 ,  A61P29/00 ,  A61P35/00 ,  A61P9/00 ,  A61P25/00

CPC分类号： C07D473/00 ,  A61K31/52 ,  C07D473/32

摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

摘要翻译： 本文提供具有以下结构的氨基嘌呤化合物：其中R1，R2和R3如本文所定义，包含有效量的氨基嘌呤化合物的组合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症 ，炎性病症，黄斑变性，缺血再灌注损伤，疼痛及相关综合征，疾病相关性消耗，石棉相关病症，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症，包括施用有效量的 氨基嘌呤化合物对需要的患者。

公开(公告)号：US20090275564A1

公开(公告)日：2009-11-05

申请号：US12404413

申请日：2009-03-16

申请人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Sayee G. Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S.S. Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright

发明人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Sayee G. Hegde ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S.S. Palanki ,  Kiran Sahasrabudhe ,  John Sapienza ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright

IPC分类号： A61K31/52 ,  C07D473/16 ,  C07D413/14 ,  C07D243/08 ,  A61K31/5377 ,  A61K31/551 ,  A61P37/00 ,  A61P35/00 ,  A61P9/00

CPC分类号： A61K31/52 ,  C07D473/32

摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

摘要翻译： 本文提供具有以下结构的氨基嘌呤化合物：其中R1，R2和R3如本文所定义，包含有效量的氨基嘌呤化合物的组合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症， 炎性病症，黄斑变性，缺血再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关病症，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症包括给予有效量的氨基嘌呤 与需要的患者复合。

公开(公告)号：US07521446B2

公开(公告)日：2009-04-21

申请号：US11411413

申请日：2006-04-26

申请人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S. S. Palanki ,  Kiran Sahasrabudhe ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright

发明人： Ronald J. Albers ,  Leticia Ayala ,  Steven S. Clareen ,  Maria Mercedes Delgado Mederos ,  Robert Hilgraf ,  Kevin Hughes ,  Adam Kois ,  Veronique Plantevin-Krenitsky ,  Meg McCarrick ,  Lisa Nadolny ,  Moorthy S. S. Palanki ,  Kiran Sahasrabudhe ,  Yoshitaka Satoh ,  Marianne K. Sloss ,  Elise Sudbeck ,  Jonathan Wright

IPC分类号： C07D473/32 ,  A61K31/52 ,  A61P3/10 ,  A61P11/00 ,  C07D239/50 ,  C07D239/48

CPC分类号： A61K31/52 ,  C07D473/32

摘要： Provided herein are Aminopurine Compounds having the following structure: wherein R1, R2 and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

摘要翻译： 本文提供具有以下结构的氨基嘌呤化合物：其中R1，R2和R3如本文所定义，包含有效量的氨基嘌呤化合物的组合物和治疗或预防癌症，心血管疾病，肾脏疾病，自身免疫病症， 炎性病症，黄斑变性，缺血再灌注损伤，疼痛和相关综合征，疾病相关性消耗，石棉相关病症，肺动脉高压或通过抑制JNK途径可治疗或可预防的病症包括给予有效量的氨基嘌呤 与需要的患者复合。

公开(公告)号：US20050107457A1

公开(公告)日：2005-05-19

申请号：US11000462

申请日：2004-11-30

申请人： Shripad Bhagwat ,  Yoshitaka Satoh ,  Steven Sakata ,  Chris Buhr ,  Ronald Albers ,  John Sapienza ,  Veronique Plantevin ,  Qi Chao ,  Kiran Sahasrabudhe ,  Rachel Ferri

发明人： Shripad Bhagwat ,  Yoshitaka Satoh ,  Steven Sakata ,  Chris Buhr ,  Ronald Albers ,  John Sapienza ,  Veronique Plantevin ,  Qi Chao ,  Kiran Sahasrabudhe ,  Rachel Ferri

IPC分类号： A61K31/41 ,  A61K31/416 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P11/08 ,  A61P13/12 ,  A61P17/02 ,  A61P17/08 ,  A61P19/02 ,  A61P19/06 ,  A61P19/08 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P27/08 ,  A61P27/16 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  C07D231/56 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12 ,  A61K31/4162 ,  C07D43/02

CPC分类号： C07D403/12 ,  C07D231/56 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12

摘要： Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

公开(公告)号：US07220771B2

公开(公告)日：2007-05-22

申请号：US10673121

申请日：2003-09-26

申请人： Shripad S. Bhagwat ,  Yoshitaka Satoh ,  Steven T. Sakata ,  Chris A. Buhr ,  Ronald Albers ,  John Sapienza ,  Veronique Plantevin ,  Qi Chao ,  Kiran Sahasrabudhe ,  Rachel Ferri

发明人： Shripad S. Bhagwat ,  Yoshitaka Satoh ,  Steven T. Sakata ,  Chris A. Buhr ,  Ronald Albers ,  John Sapienza ,  Veronique Plantevin ,  Qi Chao ,  Kiran Sahasrabudhe ,  Rachel Ferri

IPC分类号： A61K31/416 ,  A61K31/41

CPC分类号： C07D403/12 ,  C07D231/56 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12

摘要： Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

摘要翻译： 公开了具有活性作为JNK的选择性抑制剂的化合物。 本发明的化合物是具有以下结构的吲唑衍生物：其中R 1，R 2和A如本文所定义。 这些化合物可用于治疗对JNK抑制作用有响应的广泛范围的病症。 因此，还公开了治疗这些病症的方法，以及含有一种或多种上述化合物的化合物的药物组合物。

公开(公告)号：US20050009876A1

公开(公告)日：2005-01-13

申请号：US10718185

申请日：2003-11-19

申请人： Shripad Bhagwat ,  Yoshitaka Satoh ,  Steven Sakata ,  Chris Buhr ,  Ronald Albers ,  John Sapienza ,  Veronique Plantevin ,  Qi Chao ,  Kiran Sahasrabudhe ,  Rachel Ferri ,  Rama Narla

发明人： Shripad Bhagwat ,  Yoshitaka Satoh ,  Steven Sakata ,  Chris Buhr ,  Ronald Albers ,  John Sapienza ,  Veronique Plantevin ,  Qi Chao ,  Kiran Sahasrabudhe ,  Rachel Ferri ,  Rama Narla

IPC分类号： A61K31/416 ,  C07D231/56 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12 ,  A61K31/4439 ,  A61K31/4162 ,  C07

CPC分类号： A61K31/454 ,  A61K31/416 ,  C07D231/56 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12

摘要： This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

摘要翻译： 本发明一般涉及吲唑化合物用于治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，例如增殖性疾病，炎性疾病，异常血管发生及其相关疾病，动脉粥样硬化，黄斑变性，糖尿病，肥胖症，疼痛 和别的。 所述方法包括向有需要的患者施用有效量的抑制，调节或调节酪氨酸激酶信号转导的吲唑化合物。 本文给出了新的吲唑化合物或其药学上可接受的盐。